Paraoxonase 1 (PON1)

Paraoxonase 1 (PON1) (EC 3.1.8.1 / EC 3.1.1.2 / EC 3.1.1.81) is a hepatocyte-secreted, calcium-dependent glycoprotein enzyme (355 amino acids, ~43 kDa) encoded by the PON1 gene on human chromosome 7q21.3 (9 exons, positioned in a tandem paralogous cluster alongside PON2 and PON3) that circulates in mammalian bloodstream physically anchored to high-density lipoprotein (HDL) particles. Although named historically for its ability to hydrolyze paraoxon—the lethal active oxon metabolite of the synthetic agricultural insecticide parathion—PON1 evolved in vertebrates as a promiscuous lipolactonase and peroxidized-phospholipid hydrolase. On the surface of apolipoprotein A-I (apoA-I)-containing HDL particles, PON1 hydrolyzes bioactive fatty-acid lactones, 5-hydroxyeicosatetraenoic acid (5-HETE) lactone, N-acyl-homoserine lactone (AHL) bacterial quorum-sensing signals, pro-atherogenic homocysteine thiolactone, and oxidized phosphatidylcholine hydroperoxides on low-density lipoproteins (LDL), thereby protecting vascular endothelium against atherosclerosis and oxidative lipid peroxidation.

Simultaneously, in terrestrial mammals, plasma PON1 serves as the primary catalytic bioscavenger that hydrolyzes and detoxifies organophosphate (OP) oxon anticholinesterases—including chlorpyrifos-oxon, diazoxon, paraoxon, and G-series chemical nerve agents (sarin and soman)—before they can reach and irreversibly phosphorylate synaptic acetylcholinesterase (AChE). In 2018, comparative genomics across 68 mammalian species by Wynn Meyer, Nathan Clark, and Clement Furlong revealed a striking evolutionary surprise: PON1 has undergone independent, convergent pseudogenization (via frameshift deletions, premature stop codons, and relaxed purifying selection, dN/dS ω → 0.85–1.00) in every major secondary marine mammal lineage (Cetacea, Pinnipedia, and Sirenia), leaving whales, dolphins, seals, sea lions, and manatees completely devoid of plasma organophosphate-detoxifying capacity and acutely vulnerable to coastal agricultural pesticide runoff.

High-Density Lipoprotein (HDL) Anchoring and Tunnel Architecture

Crystal structures of recombinant mammalian PON1 solved by Dan Tawfik, Joel Sussman, and colleagues (2004) at 2.2-Å resolution established that PON1 folds into a six-bladed β-propeller (Blades 1–6, each composed of four antiparallel β-strands A–D), closed via a disulfide bridge (Cys42–Cys353) uniting the N- and C-termini. Unlike secreted proteins whose N-terminal leader peptide is cleaved in the endoplasmic reticulum, PON1 retains its hydrophobic N-terminal α-helix (H1, residues 1–28) and an adjacent surface amphipathic helix (H2, residues 185–202). Together with H3, these hydrophobic helices form an interfacial lipid-binding canopy above the active site that inserts directly into the phospholipid monolayer of HDL particles, stabilized by specific high-affinity interactions with apolipoprotein A-I (apoA-I) (which boosts PON1 lactonase stability and V_max ~5- to 20-fold).

Buried at the central axis of the β-propeller tunnel are two essential calcium ions (Ca1 and Ca2) separated by 7.4 Å, which perform distinct structural and catalytic functions:

1. The Structural Calcium (Ca2, inner tunnel): Buried deep inside the central water-filled tunnel and coordinated with sub-nanomolar affinity (K_d ≈ 4 × 10⁻¹⁰ M) by Asp54, Asp169, the backbone carbonyl of Ile117, and water molecules. Removal of Ca2 by EDTA chelators causes irreversible denaturation of the six-bladed β-propeller fold.
2. The Catalytic Calcium (Ca1, active-site bottom): Positioned at the floor of the hydrophobic active-site cavity (K_d ≈ 3.6 × 10⁻⁷ M) and coordinated by five protein oxygen ligands—Asn168, Asn224, Asp269, Asn270, and Glu53—plus one water/phosphate oxygen.

Catalytic Mechanism for Lactones vs Organophosphate Oxons

As demonstrated by Tawfik's directed-evolution and kinetic isotope studies, PON1 is natively a lactonase (k_cat/K_M ≈ 10⁶ M⁻¹ s⁻¹ for dihydrocoumarin and δ-valerolactone) whose active site fortuitously accommodates synthetic phosphotriesters (paraoxon, chlorpyrifos-oxon):

• Native Lactonase & Arylesterase Catalysis (His115–His134 Dyad + Ca1): For lactone and phenyl-acetate substrates, the His115–His134 catalytic dyad (where His134 hydrogen-bonds to His115 to raise its basicity) activates a water molecule to attack the lactone carbonyl carbon, while oxyanion Ca1 polarizes the carbonyl oxygen (C=O) and stabilizes the negatively charged tetrahedral intermediate.
• Promiscuous Phosphotriesterase (OP Oxon) Catalysis: For bulky tetrahedral organophosphate triesters (P=O), mutating His115 (H115W) abolishes lactonase activity while actually enhancing paraoxonase activity. In phosphotriester hydrolysis, Ca1, assisted by Asp269 and Glu53, coordinates the phosphoryl oxygen (P=O) and directly activates a hydroxide nucleophile (OH⁻) for in-line S_N2(P) attack on the phosphorus center, expelling p-nitrophenol (from paraoxon) or 3,5,6-trichloro-2-pyridinol (from chlorpyrifos-oxon).

In human populations, plasma PON1 detoxifying capacity varies by up to 40-fold between individuals, governed by two major functional polymorphisms:

1. The Coding Gln192Arg (Q192R, rs662) Substrate-Specificity Switch: Residue 192 lies in the active-site wall adjacent to the H2 amphipathic helix. Replacing neutral glutamine (192Q, allele frequency ~70% in Europeans, ~35% in East Asians and Africans) with positively charged arginine (192R) electrostatically reorients the leaving group of bulky organophosphates. The 192R allozyme hydrolyzes paraoxon ~8-fold faster and chlorpyrifos-oxon ~2-fold faster than 192Q, whereas the 192Q allozyme hydrolyzes diazoxon, sarin, soman, and oxidized phospholipid lactones more rapidly than 192R.
2. The Promoter −108C>T (rs705379) and Coding Leu55Met (L55M, rs854560) Expression Polymorphisms: Nucleotide −108 lies inside a consensus binding box for the ubiquitous transcription factor Sp1. The −108C allele binds Sp1 strongly and drives ~2-fold higher hepatic PON1 transcription than −108T, while 55L (in linkage disequilibrium with −108C) confers greater protein thermal stability than 55M. Furthermore, human neonates express only ~20%–25% of adult plasma PON1 levels until 6–15 months of age, creating a critical developmental window of vulnerability to agricultural organophosphate neurotoxicity.

Why Whales, Manatees, and Seals Lost Functional PON1

In 2018, Meyer, Clark, Furlong, and colleagues screened the genomes of 68 mammal species for genes that specifically lost function during the independent evolutionary transitions of terrestrial mammals back to the marine environment (which occurred separately in Cetacea ~50 Ma, Sirenia ~50 Ma, and Pinnipedia ~25 Ma). Across all terrestrial mammals examined, PON1 remained intact under purifying selection (ω ≈ 0.21). By contrast, PON1 accumulated disabling lesions—frameshift indels, mutated GT–AG splice junctions, and premature stop codons (and complete absence of plasma diazoxonase and chlorpyrifos-oxonase enzymatic activity in blood plasma assays)—across:

• All Cetaceans: Bottlenose dolphin (Tursiops truncatus), killer whale (Orcinus orca), sperm whale, minke whale, and bowhead whale (inactivated on the ancestral cetacean branch ~53 Ma).
• All Sirenians: Florida manatee (Trichechus manatus) and Steller's sea cow (Hydrodamalis gigas).
• Most Pinnipeds: Weddell seal, Hawaiian monk seal, elephant seal, and California sea lion (as well as the semiaquatic sea otter and beaver, with relaxed selection ω → 0.88–1.00).

Why did PON1 repeatedly become a pseudogene in diving mammals, mirroring the convergent loss of GULO in frugivores and ANGPTL3 relaxation in divers? Prolonged breath-hold diving subjects marine mammals to repeated bouts of peripheral ischemia and reperfusion, generating bursts of reactive oxygen species (ROS) and lipid hydroperoxides on cell membranes and lipoproteins. Under extreme diving-induced oxidative load, PON1 on HDL is itself oxidatively inactivated at its free Cys284 sulfhydryl group and may generate cytotoxic lysophosphatidylcholine or pro-inflammatory oxidized free fatty acids during reperfusion; simultaneously, marine mammals expanded glutathione peroxidase (GPX), peroxiredoxin, and paraoxonase paralog PON3/PON2 antioxidant pathways, rendering PON1 dispensable or deleterious in the ancestral pre-industrial ocean.

Tragically, while losing PON1 carried no penalty in the ancient ocean, modern industrial agriculture discharges thousands of tons of organophosphate insecticides (chlorpyrifos, diazinon, malathion) into coastal estuaries, seagrass beds (consumed by manatees), and marine food webs—leaving PON1-null marine mammals without enzymatic defense against anticholinesterase neurotoxicity.

If synthetic organophosphate pesticides were invented in the 20th century, why do terrestrial mammals possess an enzyme called "paraoxonase"?

"Paraoxonase" is an historical misnomer based on the synthetic substrate (paraoxon) first used by Abraham Mazur in 1946 to assay plasma esterase activity. Directed-evolution and structural studies by Dan Tawfik proved that PON1 evolved in vertebrates as a lipolactonase (k_cat/K_M ≈ 10⁶ M⁻¹ s⁻¹) that hydrolyzes endogenous oxidized fatty-acid lactones, homocysteine thiolactone, and bacterial N-acyl-homoserine lactone (AHL) quorum-sensing molecules on HDL. Its active-site catalytic calcium (Ca1) fortuitously accommodates the tetrahedral phosphorus atom of synthetic organophosphate oxons via catalytic promiscuity.

Why are human infants and PON1 192Q/Q homozygotes more vulnerable to chlorpyrifos neurotoxicity?

Chlorpyrifos is oxidized by hepatic cytochrome P450 enzymes into chlorpyrifos-oxon, which irreversibly inhibits brain acetylcholinesterase unless rapidly hydrolyzed by plasma PON1. First, the human PON1-192Q allozyme hydrolyzes chlorpyrifos-oxon at roughly half the catalytic efficiency of the 192R allozyme. Second, human newborns and infants (<1 year of age) express only ~20% to 25% of adult hepatic PON1 levels, meaning a neonate with the −108T/T and 192Q/Q genotype can have a >50-fold lower capacity to detoxify chlorpyrifos-oxon than an adult with the −108C/C and 192R/R genotype.

Why did whales, dolphins, manatees, and seals independently lose the PON1 gene?

Cetaceans, sirenians, and pinnipeds descended from three separate terrestrial mammal ancestors (artiodactyls, afrotherians, and carnivores) that all possessed functional PON1. Upon transitioning to breath-hold marine diving, each lineage independently accumulated frameshift and nonsense mutations in PON1 (dN/dS ω → 1.0). Diving mammals evolved alternative glutathione-based antioxidant defenses against ischemia–reperfusion stress and experienced zero dietary exposure to terrestrial plant/fungal lactone toxins in the pre-industrial ocean, relaxing purifying selection on PON1—an evolutionary trade-off that now leaves marine mammals defenseless against agricultural organophosphate runoff.

1. Harel, M., Aharoni, A., Gaidukov, L., et al. (2004). "Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes." Nature Structural & Molecular Biology, 11(5), 412–419. https://doi.org/10.1038/nsmb767
2. Meyer, W. K., Jamison, J., Richter, R., et al. (2018). "Ancient convergent losses of Paraoxonase 1 yield potential risks for modern marine mammals." Science, 361(6402), 591–594. https://doi.org/10.1126/science.aap7714
3. Humbert, R., Adler, D. A., Disteche, C. M., et al. (1993). "The molecular basis of the human serum paraoxonase activity polymorphism." Nature Genetics, 3(1), 73–76. https://doi.org/10.1038/ng0193-73
4. Khersonsky, O., & Tawfik, D. S. (2005). "Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase." Biochemistry, 44(16), 6371–6382. https://doi.org/10.1021/bi047440d